Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial.
В этом разделе статьи показаны на английском.
Viking Therapeutics Stock Soars 36% on Weight-Loss Drug Data. Why It's Not Too Late to Buy the Stock.
Редакция Trade News (2026-09-30) фиксирует рынок: Key PointsViking Therapeutics' leading candidate recently performed well in a maintenance clinical trial. Первоисточник — оригинал Nasdaq Market Structure (nasdaq.com).